The EMA has given a positive opinion for the exceptional circumstances authorization of Imreplys (sargramostim) to treat myelosuppression after acute radiation exposure. Medscape Medical News
The EMA has given a positive opinion for the exceptional circumstances authorization of Imreplys (sargramostim) to treat myelosuppression after acute radiation exposure. Medscape Medical News